Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City.
OBJECTIVE
To evaluate the association of 2008-9 seasonal trivalent inactivated vaccine with cases of influenza A/H1N1 during the epidemic in Mexico.


METHODS
Frequency matched case-control study.


METHODS
Specialty hospital in Mexico City, March to May 2009.


METHODS
60 patients with laboratory confirmed influenza A/H1N1 and 180 controls with other diseases (not influenza-like illness or pneumonia) living in Mexico City or the State of Mexico and matched for age and socioeconomic status.


METHODS
Odds ratio and effectiveness of trivalent inactivated vaccine against influenza A/H1N1.


RESULTS
Cases were more likely than controls to be admitted to hospital, undergo invasive mechanical ventilation, and die. Controls were more likely than cases to have chronic conditions that conferred a higher risk of influenza related complications. In the multivariate model, influenza A/H1N1 was independently associated with trivalent inactivated vaccine (odds ratio 0.27, 95% confidence interval 0.11 to 0.66) and underlying conditions (0.15, 0.08 to 0.30). Vaccine effectiveness was 73% (95% confidence interval 34% to 89%). None of the eight vaccinated cases died.


CONCLUSIONS
Preliminary evidence suggests some protection from the 2008-9 trivalent inactivated vaccine against pandemic influenza A/H1N1 2009, particularly severe forms of the disease, diagnosed in a specialty hospital during the influenza epidemic in Mexico City.
Garcia-Garcia
Lourdes
L
Instituto Nacional de Salud Pública, Cuernavaca, Mor, Mexico.
Valdespino-Gómez
Jose Luis
JL
Lazcano-Ponce
Eduardo
E
Jimenez-Corona
Aida
A
Higuera-Iglesias
Anjarath
A
Cruz-Hervert
Pablo
P
Cano-Arellano
Bulmaro
B
Garcia-Anaya
Antonio
A
Ferreira-Guerrero
Elizabeth
E
Baez-Saldaña
Renata
R
Ferreyra-Reyes
Leticia
L
Ponce-de-León-Rosales
Samuel
S
Alpuche-Aranda
Celia
C
Rodriguez-López
Mario Henry
MH
Perez-Padilla
Rogelio
R
Hernandez-Avila
Mauricio
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D015995:Prevalence; D016896:Treatment Outcome; D015164:Vaccines, Inactivated
D007252:Influenza Vaccines; D015164:Vaccines, Inactivated